Autism is Treatable!
The Petitioners request that the Prime Minister urges the Secretary of State for Health to:
* Instruct the Department of Health Research & Development
department to commission research into the promising biomedical
treatments of: gastrointestinal cleansing and healing including
exclusion diets, vitamin and mineral, essential fatty acid and enzyme
supplementation; immune modulation to address dysregulated
immune systems; the repair of impaired detoxification systems and
the removal of accumulated toxic heavy metals.
* Ensure that appropriate assessment and treatment is made available
on the NHS in response to research findings.
* Mandate the Autism Research Co-ordination Group to undertake
ongoing consultation with parents groups into parental priorities for
research and treatment.
* Mandate the Autism Research Co-ordination Group to seek
permanent representation from parents groups.
* Commission a Minister for Autism and Developmental Disorders.
* Instruct the Department of Health Research & Development
department to commission research into the promising biomedical
treatments of: gastrointestinal cleansing and healing including
exclusion diets, vitamin and mineral, essential fatty acid and enzyme
supplementation; immune modulation to address dysregulated
immune systems; the repair of impaired detoxification systems and
the removal of accumulated toxic heavy metals.
* Ensure that appropriate assessment and treatment is made available
on the NHS in response to research findings.
* Mandate the Autism Research Co-ordination Group to undertake
ongoing consultation with parents groups into parental priorities for
research and treatment.
* Mandate the Autism Research Co-ordination Group to seek
permanent representation from parents groups.
* Commission a Minister for Autism and Developmental Disorders.
To the Prime Minister
The petition of parents, carers, relatives and friends of children with autism declares that:
Clinical experience from doctors in the US [1,2] and a smaller number in the UK has shown that children with autism have underlying medical problems and that when these problems are treated, the children's health improves AND there is a (sometimes very significant) amelioration in autistic symptoms. Research results are already available to demonstrate the common medical issues and the efficacy of some of the biomedical treatments [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17].
A recent NAS survey estimates that 1 in 80 primary school age children is on the autistic spectrum [18]. The corresponding figure for secondary school age children is 1 in 268. This demonstrates that autism rates are increasing dramatically and pose a significant risk to the general population. A recent Institute of Psychiatry study shows that the cost of caring for a person with autism is estimated to be £2.94 million during their lifetime [19].
Parents who wish to assess and treat their children biomedically in the UK are unable to access facilities on the NHS: they are told that there is no scientific evidence to validate biomedical testing and treatment for autism. The lack of `scientific evidence' stems from the medical profession's failure to accept the findings from research that has already been carried out, and the government's reluctance to ensure that research to evaluate biomedical testing and treatment is undertaken.
The Mapping Autism Research report [20] demonstrated the imbalance of autism research, with low levels of research into interventions and the need to make research more participative.
The NAS survey of members [21] revealed that members view research into biomedical treatments for autism as their top priority.
The Petitioners therefore request that the Prime Minister urges the Secretary of State for Health to:
* Instruct the Department of Health Research & Development
department to commission research into the promising biomedical
treatments of: gastrointestinal cleansing and healing including
exclusion diets, vitamin and mineral, essential fatty acid and enzyme
supplementation; immune modulation to address dysregulated
immune systems; the repair of impaired detoxification systems and
the removal of accumulated toxic heavy metals.
* Ensure that appropriate assessment and treatment is made available
on the NHS in response to research findings.
* Mandate the Autism Research Co-ordination Group to undertake
ongoing consultation with parents groups into parental priorities for
research and treatment.
* Mandate the Autism Research Co-ordination Group to seek
permanent representation from parents groups.
* Commission a Minister for Autism and Developmental Disorders.
References:
[1]Children with Starving Brains
McCandless J
Bramble Books 2005
[2]Autism: effective biomedical treatments
Pangborn J and Baker SM
Autism Research Institute; 2nd Edition Sept. 2005
[3]Sulphation deficit in "low-functioning" autistic children: a pilot study.
Alberti A, Pirrone P, Elia M, Waring RH, Romano C.
Biol Psychiatry. 1999 Aug 1; 46(3): 420-4.
[4] Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism.
Martineau J, Barthelemy C, Garreau B, Lelord G.
Biol Psychiatry. 1985 May; 20(5): 467-78.
[5] A randomised, controlled study of dietary intervention in autistic syndromes.
Knivsberg AM, Reichelt KL, Hoien T, Nodland M.
Nutritional Neuroscience. 2002 Vol 5(4): 251-261
[6] Gastrointestinal microflora studies in late-onset autism.
Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M, Sandler R, Wexler H, Marlowe EM, Collins MD, Lawson PA, Summanen P, Baysallar M, Tomzynski TJ, Read E, Johnson E, Rolfe R, Nasir P, Shah H, Haake DA, Manning P, Kaul A.
Clin Infect Dis. 2002 Sep 1; 35(Suppl 1): S6-S16.
[7] Essential fatty acids and phospholipase A2 in autistic spectrum disorders.
Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM, Glen AC.
Prostaglandins Leukot Essent Fatty Acids. 2004 Oct; 71(4): 201-204
[8] Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders?
Bell JG, Sargent JR, Tocher DR, Dick JR.
Prostaglandins Leukot Essent Fatty Acids. 2000 Jul-Aug; 63(1-2): 21-5.
[9] Abnormal measles-mumps-rubella antibodies and CNS autoimmunity in children with autism.
Singh VK, Lin SX, Newell E, Nelson C.
J Biomed Sci. 2002 Jul-Aug; 9(4): 359-64.
[10] Immunity, neuroglia and neuroinflammation in autism
Pardo CA, Vargas DL, Zimmerman AW.
Int Rev Psychiatry. 2006 Jan; 17(6): 485-95.
[11] Neuroglial activation and neuroinflammation in the brain of patients with autism.
Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA.
Ann Neurol. 2005 Dec; 57(1): 67-81.
[12] The significance of ileo-colonic lymphoid nodular hyperplasia in children with autistic spectrum disorder.
Wakefield AJ, Ashwood P, Limb K, Anthony A.
Eur J Gastroenterol Hepatol. 2005 Aug; 17(8): 827-36.
[13] Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention.
Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B.
Neuropsychobiology. 2005; 51(2): 77-85.
[14] Large brains in autism: the challenge of pervasive abnormality.
Herbert MR.
Neuroscientist. 2005 Oct; 11(5): 417-40.
[15] Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.
James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA.
Am J Clin Nutr. 2004 Dec; 80(6): 1611-7.
[16] Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal.
Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC.
Mol Psychiatry. 2004 Apr; 9(4): 358-70.
[17] Neurotoxic effects of postnatal thimerosal are mouse strain dependent.
Hornig M, Chian D, Lipkin WI.
Mol Psychiatry. 2004 Sep; 9(9):833-45.
[18] Autism in schools crisis or challenge?
Barnard J, Potter D, Broach S and Prior A.
NAS report 2002
[19] The economic impact of autism in Britain
Järbrink K and Knapp M.
Autism 2001 5:7-22
[20] Mapping Autism Research
Charman C and Clare P
NAS 2004
[21] Researching interventions in ASD and priorities for research: surveying the membership of the NAS
Mills R and Wing L
NAS 2005
signersignerThe petition of parents, carers, relatives and friends of children with autism declares that:
Clinical experience from doctors in the US [1,2] and a smaller number in the UK has shown that children with autism have underlying medical problems and that when these problems are treated, the children's health improves AND there is a (sometimes very significant) amelioration in autistic symptoms. Research results are already available to demonstrate the common medical issues and the efficacy of some of the biomedical treatments [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17].
A recent NAS survey estimates that 1 in 80 primary school age children is on the autistic spectrum [18]. The corresponding figure for secondary school age children is 1 in 268. This demonstrates that autism rates are increasing dramatically and pose a significant risk to the general population. A recent Institute of Psychiatry study shows that the cost of caring for a person with autism is estimated to be £2.94 million during their lifetime [19].
Parents who wish to assess and treat their children biomedically in the UK are unable to access facilities on the NHS: they are told that there is no scientific evidence to validate biomedical testing and treatment for autism. The lack of `scientific evidence' stems from the medical profession's failure to accept the findings from research that has already been carried out, and the government's reluctance to ensure that research to evaluate biomedical testing and treatment is undertaken.
The Mapping Autism Research report [20] demonstrated the imbalance of autism research, with low levels of research into interventions and the need to make research more participative.
The NAS survey of members [21] revealed that members view research into biomedical treatments for autism as their top priority.
The Petitioners therefore request that the Prime Minister urges the Secretary of State for Health to:
* Instruct the Department of Health Research & Development
department to commission research into the promising biomedical
treatments of: gastrointestinal cleansing and healing including
exclusion diets, vitamin and mineral, essential fatty acid and enzyme
supplementation; immune modulation to address dysregulated
immune systems; the repair of impaired detoxification systems and
the removal of accumulated toxic heavy metals.
* Ensure that appropriate assessment and treatment is made available
on the NHS in response to research findings.
* Mandate the Autism Research Co-ordination Group to undertake
ongoing consultation with parents groups into parental priorities for
research and treatment.
* Mandate the Autism Research Co-ordination Group to seek
permanent representation from parents groups.
* Commission a Minister for Autism and Developmental Disorders.
References:
[1]Children with Starving Brains
McCandless J
Bramble Books 2005
[2]Autism: effective biomedical treatments
Pangborn J and Baker SM
Autism Research Institute; 2nd Edition Sept. 2005
[3]Sulphation deficit in "low-functioning" autistic children: a pilot study.
Alberti A, Pirrone P, Elia M, Waring RH, Romano C.
Biol Psychiatry. 1999 Aug 1; 46(3): 420-4.
[4] Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism.
Martineau J, Barthelemy C, Garreau B, Lelord G.
Biol Psychiatry. 1985 May; 20(5): 467-78.
[5] A randomised, controlled study of dietary intervention in autistic syndromes.
Knivsberg AM, Reichelt KL, Hoien T, Nodland M.
Nutritional Neuroscience. 2002 Vol 5(4): 251-261
[6] Gastrointestinal microflora studies in late-onset autism.
Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M, Sandler R, Wexler H, Marlowe EM, Collins MD, Lawson PA, Summanen P, Baysallar M, Tomzynski TJ, Read E, Johnson E, Rolfe R, Nasir P, Shah H, Haake DA, Manning P, Kaul A.
Clin Infect Dis. 2002 Sep 1; 35(Suppl 1): S6-S16.
[7] Essential fatty acids and phospholipase A2 in autistic spectrum disorders.
Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM, Glen AC.
Prostaglandins Leukot Essent Fatty Acids. 2004 Oct; 71(4): 201-204
[8] Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders?
Bell JG, Sargent JR, Tocher DR, Dick JR.
Prostaglandins Leukot Essent Fatty Acids. 2000 Jul-Aug; 63(1-2): 21-5.
[9] Abnormal measles-mumps-rubella antibodies and CNS autoimmunity in children with autism.
Singh VK, Lin SX, Newell E, Nelson C.
J Biomed Sci. 2002 Jul-Aug; 9(4): 359-64.
[10] Immunity, neuroglia and neuroinflammation in autism
Pardo CA, Vargas DL, Zimmerman AW.
Int Rev Psychiatry. 2006 Jan; 17(6): 485-95.
[11] Neuroglial activation and neuroinflammation in the brain of patients with autism.
Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA.
Ann Neurol. 2005 Dec; 57(1): 67-81.
[12] The significance of ileo-colonic lymphoid nodular hyperplasia in children with autistic spectrum disorder.
Wakefield AJ, Ashwood P, Limb K, Anthony A.
Eur J Gastroenterol Hepatol. 2005 Aug; 17(8): 827-36.
[13] Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention.
Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B.
Neuropsychobiology. 2005; 51(2): 77-85.
[14] Large brains in autism: the challenge of pervasive abnormality.
Herbert MR.
Neuroscientist. 2005 Oct; 11(5): 417-40.
[15] Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.
James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA.
Am J Clin Nutr. 2004 Dec; 80(6): 1611-7.
[16] Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal.
Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC.
Mol Psychiatry. 2004 Apr; 9(4): 358-70.
[17] Neurotoxic effects of postnatal thimerosal are mouse strain dependent.
Hornig M, Chian D, Lipkin WI.
Mol Psychiatry. 2004 Sep; 9(9):833-45.
[18] Autism in schools crisis or challenge?
Barnard J, Potter D, Broach S and Prior A.
NAS report 2002
[19] The economic impact of autism in Britain
Järbrink K and Knapp M.
Autism 2001 5:7-22
[20] Mapping Autism Research
Charman C and Clare P
NAS 2004
[21] Researching interventions in ASD and priorities for research: surveying the membership of the NAS
Mills R and Wing L
NAS 2005
Voir plus de pétitions:
Vous avez désactivé JavaScript sur votre navigateur. Sans JavaScript, il se peut que notre site Internet ne fonctionne pas correctement.
En signant, vous acceptez les conditions de service de Care2
Vous pouvez gérer vos abonnements à tout moment.
Vous ne parvenez pas à signer cette pétition ?? Faites-le nous savoir.